219 results on '"Dhillon, A"'
Search Results
2. Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes
3. Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders
4. Comparison of Molecular Profile and Clinical Outcomes of Essential Thrombocytosis between Hispanic and Non-Hispanic Patients in the Central Valley of California
5. Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes
6. Impact of MRA Echo Time on Stroke Prevention Therapy in Pediatric Patients with Sickle Cell Disease
7. Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients
8. Picasso: An Open-Source Machine Learning Schema for Annotating Images in Hematology
9. Real-World Outcomes and Cardiac Implications of FLT3 Inhibitors in Acute Myeloid Leukemia
10. Real-World Outcomes of IDH Mutant AML Patients Treated with or without IDH Inhibitors
11. Comparison of Molecular Profile and Clinical Outcomes of Essential Thrombocytosis between Hispanic and Non-Hispanic Patients in the Central Valley of California
12. Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia
13. Clinical and Mechanistic Relationship of T -Cell Large Granular Lymphocytic Leukemia ( TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS)
14. Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
15. Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
16. Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders
17. Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia
18. External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs
19. Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients
20. Analysis of the clonal growth and differentiation dynamics of primitive barcoded human cord blood cells in NSG mice
21. The secreted lymphangiogenic factor CCBE1 is essential for fetal liver erythropoiesis
22. Enhanced normal short-term human myelopoiesis in mice engineered to express human-specific myeloid growth factors
23. Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation
24. Real-World Outcomes and Cardiac Implications of FLT3 Inhibitors in Acute Myeloid Leukemia
25. External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs
26. Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients
27. Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia
28. Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
29. Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients
30. Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
31. Clinical and Mechanistic Relationship of T -Cell Large Granular Lymphocytic Leukemia ( TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS)
32. Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia
33. Real-World Outcomes of IDH Mutant AML Patients Treated with or without IDH Inhibitors
34. Picasso: An Open-Source Machine Learning Schema for Annotating Images in Hematology
35. Inhibition of pathogenic SHIV replication in macaques treated with antisense DNA of interleukin-4
36. An Insight into the Impact of Hemophilia a on Daily Life According to Disease Severity: A Preliminary Analysis of the CHESS II Study
37. Impact of MRA Echo Time on Stroke Prevention Therapy in Pediatric Patients with Sickle Cell Disease
38. A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
39. Elucidating the Importance and Regulation of Key Enhancers for Human MEIS1 Expression
40. Co-Occurring Mutations in ASXL1 and SRSF2 Define a Unique, Prognostically Relevant Chromatin-Spliceosome Gene Signature in De Novo acute Myeloid Leukemia
41. Epigenetic Age Acceleration in Hematological Malignancies: Beyond Chronological Age, Clinical Implications, and Therapeutic Perspectives
42. Concordance/Discordance of Paired Sequencing of Bone Marrow Tissue and Myeloid Sarcoma Samples- a Meta-Analysis
43. Trends in Heparin-Induced Thrombocytopenia in the Pre-Pandemic and Peak-Pandemic Era, and Impact of COVID-19 on Mortality; An Analysis Via the National Inpatient Sample
44. Differential Impact of Domain Stratified Non-R882 DNMT3A Mutations in Myeloid Neoplasms
45. Predictors of Immune Thrombocytopenic Purpura in COVID-19 Positive Elderly Admitted in the Pre-Vaccination Era of the Pandemic; An Analysis Via the 2020 National Inpatient Sample
46. Non-Canonical Double Mutant DNMT3A mutations: Clinical and Biological Significance in Myeloid Neoplasms
47. Co-Mutational Patterns with BCOR Influences Biological Characteristics and Clinical Outcomes of Myeloid Neoplasms
48. Clinical and Molecular Characteristics of NPM1MTDe Novo AML ( NPM1MT dnAML) Differ from NPM1MT therapy-associated AML ( NPM1MT tAML)
49. Automated Peripheral Smear Recognition and Classification of LGL Leukemia Using Machine Learning
50. Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.